Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca; Genentech, Inc.; and Merck & Co., Inc.

Hepatocellular Carcinoma Tumor Board: The Experts Address Novel Regimens and Emerging Sequencing Considerations

Release Date: July 15, 2020
Expiration Date: July 15, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in hepatocellular carcinoma (HCC) treatment and clinical research for an in-depth mock tumor board that will assess the clinical impact of recent and emerging trial data for novel therapies in HCC treatment. A series of case presentations are presented, with clinical trial data tightly integrated to illuminate frontline, subsequent-line, sequencing, and optimizing multidisciplinary management throughout the HCC treatment paradigm. Adverse events and management are tied to case presentations. Future directions in the field are also addressed and considered regarding how recent developments and highly anticipated trials may shape care.

This educational activity is an archive of the live virtual symposium held on June 25, 2020.

Acknowledgment of Commercial Support

This educational activity is supported by educational grants from AstraZeneca; Genentech, Inc.; and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of HCC. Hepatologists, gastroenterologists, nurse practitioners, physician assistants, nurses, and other health care providers involved in the treatment and management of patients with HCC are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe HCC biology and biomarkers in the context of how they have informed rational drug development and clinical decision-making in the HCC setting
  • Evaluate recently reported clinical trial data regarding the safety and efficacy of current and emerging agents for the treatment of HCC
  • Identify strategies to optimize therapeutic sequencing in the treatment of HCC based on the best available evidence
  • Integrate emerging data into the context of clinical scenarios to optimize effective and safe multidisciplinary management of HCC along the treatment continuum

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


R. Kate (Katie) Kelley, MD
R. Kate (Katie) Kelley, MD
Associate Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California San Francisco
San Francisco, CA

Disclosures: Grant Research Support: Research support to institution: Adaptimmune, Agios, AstraZeneca, Bayer, BMS, Eli Lilly, EMD Serono, Exelixis, Merck, Novartis, QED, Partner Therapeutics, Taiho; Consultant: Genentech/Roche, Gilead; Other: Travel support for satellite symposium from lpsen.

Jordi Bruix, MD, PhD
Jordi Bruix, MD, PhD
Professor of Medicine
University of Barcelona
Director, Barcelona Clinic Liver Cancer Group
Hospital Clinic of Barcelona
Barcelona, Spain

Disclosures: Grant Research Support: Bayer; Consultant: AbbVie, ArQule, MedImmune/AstraZeneca, Basilea, Bayer Schering Pharma, BMS, BTG/Biocompatibles, Eisai, Gilead, Ipsen, Nerviano, Novartis, Polaris, Roche, Sirtex, Sanofi, Terumo.

Lipika Goyal, MD, MPhil
Lipika Goyal, MD, MPhil
Assistant Professor of Medicine
Gastrointestinal Medical Oncologist
Mass General Cancer Center
Massachusetts General Hospital
Boston, MA

Disclosures: Consultant: Agios Pharmaceuticals, Agios Advisory Board, Alentis Therapeutics AG, AstraZeneca, Debiopharm Group, H3 Biomedicine, QED, KLUS Pharmaceuticals, Taiho Pharmaceutical, Incyte.

Augusto Villanueva MD, PhD
Augusto Villanueva MD, PhD
Assistant Professor
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Consultant: NGM Biopharmaceuticals, Gilead.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By